Molecular Pharmacology: 50 (4)

October 01, 1996; Volume 50,Issue 4

You have access
Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit.
K Williams, J Chao, K Kashiwagi, T Masuko and K Igarashi

Molecular Pharmacology October 1996, 50 (4) 701-708;
You have access
Identification and characterization of novel somatostatin antagonists.
R T Bass, B L Buckwalter, B P Patel, M H Pausch, L A Price, J Strnad and J R Hadcock

Molecular Pharmacology October 1996, 50 (4) 709-715;
You have access
Agonist binding and protein kinase C activation stimulate phosphorylation of the gastrin-releasing peptide receptor at distinct sites.
B Y Williams, Y Wang and A Schonbrunn

Molecular Pharmacology October 1996, 50 (4) 716-727;
You have access
Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
D L Gustafson, H D Beall, E M Bolton, D Ross and C A Waldren

Molecular Pharmacology October 1996, 50 (4) 728-735;
You have access
Structural determinants of substrates for the prostaglandin transporter PGT.
S Itoh, R Lu, Y Bao, J D Morrow, L J Roberts and V L Schuster

Molecular Pharmacology October 1996, 50 (4) 736-742; DOI: https://doi.org/10.1124/mol.50.4.736
You have access
Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells.
G Nickenig and T J Murphy

Molecular Pharmacology October 1996, 50 (4) 743-751;
You have access
5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
O Massot, J C Rousselle, M P Fillion, B Grimaldi, I Cloëz-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion

Molecular Pharmacology October 1996, 50 (4) 752-762;
You have access
Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells.
L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima

Molecular Pharmacology October 1996, 50 (4) 763-769;
You have access
Ligand-binding characteristics and related structural features of the expressed goldfish kainate receptors: identification of a conserved disulfide bond and three residues important for ligand binding.
Z G Wo and R E Oswald

Molecular Pharmacology October 1996, 50 (4) 770-780;
You have access
Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2a6: role in metabolic activation of nasal toxicants.
C Liu, X Zhuo, F J Gonzalez and X Ding

Molecular Pharmacology October 1996, 50 (4) 781-788;
You have access
Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.
A P Kennedy, K C Mangum, J Linden and J N Wells

Molecular Pharmacology October 1996, 50 (4) 789-798;
You have access
Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.
H Canton, R B Emeson, E L Barker, J R Backstrom, J T Lu, M S Chang and E Sanders-Bush

Molecular Pharmacology October 1996, 50 (4) 799-807;
You have access
Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
S K Alahari, N M Dean, M H Fisher, R Delong, M Manoharan, K L Tivel and R L Juliano

Molecular Pharmacology October 1996, 50 (4) 808-819;
You have access
Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
A Oksche, R Schülein, C Rutz, U Liebenhoff, J Dickson, H Müller, M Birnbaumer and W Rosenthal

Molecular Pharmacology October 1996, 50 (4) 820-828;
You have access
Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.
L A Price, J Strnad, M H Pausch and J R Hadcock

Molecular Pharmacology October 1996, 50 (4) 829-837;
You have access
Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
C Sissi, G Capranico, E Menta and M Palumbo

Molecular Pharmacology October 1996, 50 (4) 838-845;
You have access
Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
W E Robinson, M Cordeiro, S Abdel-Malek, Q Jia, S A Chow, M G Reinecke and W M Mitchell

Molecular Pharmacology October 1996, 50 (4) 846-855;
You have access
Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
M C Wright, X J Wang, M Pimenta, V Ribeiro, A J Paine and M C Lechner

Molecular Pharmacology October 1996, 50 (4) 856-863;
You have access
Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins.
C Zhang, M Schmidt, C von Eichei-Streiber and K H Jakobs

Molecular Pharmacology October 1996, 50 (4) 864-869;
You have access
Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
K S Murthy and G M Makhlouf

Molecular Pharmacology October 1996, 50 (4) 870-877;
You have access
Acemannan, a beta-(1,4)-acetylated mannan, induces nitric oxide production in macrophage cell line RAW 264.7.
L Ramamoorthy, M C Kemp and I R Tizard

Molecular Pharmacology October 1996, 50 (4) 878-884;
You have access
Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation.
B R Conklin, P Herzmark, S Ishida, T A Voyno-Yasenetskaya, Y Sun, Z Farfel and H R Bourne

Molecular Pharmacology October 1996, 50 (4) 885-890;
You have access
Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
S Jacobitz, M M McLaughlin, G P Livi, M Burman and T J Torphy

Molecular Pharmacology October 1996, 50 (4) 891-899;
You have access
DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes.
M MacFarlane, N A Jones, C Dive and G M Cohen

Molecular Pharmacology October 1996, 50 (4) 900-911;
You have access
Functional coupling of rat group II metabotropic glutamate receptors to an omega-conotoxin GVIA-sensitive calcium channel in human embryonic kidney 293 cells.
B A McCool, J P Pin, P F Brust, M M Harpold and D M Lovinger

Molecular Pharmacology October 1996, 50 (4) 912-922;
You have access
Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists.
J Gomeza, S Mary, I Brabet, M L Parmentier, S Restituito, J Bockaert and J P Pin

Molecular Pharmacology October 1996, 50 (4) 923-930;
You have access
Endogenous subunits can cause ambiguities in the pharmacology of exogenous gamma-aminobutyric acidA receptors expressed in human embryonic kidney 293 cells.
S Ueno, C Zorumski, J Bracamontes and J H Steinbach

Molecular Pharmacology October 1996, 50 (4) 931-938;
You have access
Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3.
T M Norris, E Moya, I S Blagbrough and M E Adams

Molecular Pharmacology October 1996, 50 (4) 939-946;
You have access
Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
E T Piros, P L Prather, P Y Law, C J Evans and T G Hales

Molecular Pharmacology October 1996, 50 (4) 947-956;
You have access
Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
E L Barker and R D Blakely

Molecular Pharmacology October 1996, 50 (4) 957-965;
You have access
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
V J Watts and K A Neve

Molecular Pharmacology October 1996, 50 (4) 966-976;
You have access
Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
S A Hjorth, K Thirstrup and T W Schwartz

Molecular Pharmacology October 1996, 50 (4) 977-984;
You have access
Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides.
M Merkouris, I Dragatsis, G Megaritis, G Konidakis, C Zioudrou, G Milligan and Z Georgoussi

Molecular Pharmacology October 1996, 50 (4) 985-993;
You have access
The antioxidant function of the physiological content of vitamin C.
P A Glascott, M Tsyganskaya, E Gilfor, M A Zern and J L Farber

Molecular Pharmacology October 1996, 50 (4) 994-999;
You have access
Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
S M Yu, S F Chen, Y T Lau, C M Yang and J C Chen

Molecular Pharmacology October 1996, 50 (4) 1000-1009;
You have access
Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor.
D Yu, L Zhang, J L Eiselé, D Bertrand, J P Changeux and F F Weight

Molecular Pharmacology October 1996, 50 (4) 1010-1016;
You have access
5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism.
K A Berg, S Maayani and W P Clarke

Molecular Pharmacology October 1996, 50 (4) 1017-1023;
You have access
Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist.
D Ragozzino, R M Woodward, Y Murata, F Eusebi, L E Overman and R Miledi

Molecular Pharmacology October 1996, 50 (4) 1024-1030;
You have access
Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist.
N Nishigaki, M Negishi and A Ichikawa

Molecular Pharmacology October 1996, 50 (4) 1031-1037;
You have access
m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
M Schmidt, C Nehls, U Rümenapp and K H Jakobs

Molecular Pharmacology October 1996, 50 (4) 1038-1046;
You have access
Pituitary adenylate cyclase-activating peptide, carbachol, and glucose stimulate insulin release in the absence of an increase in intracellular Ca2+.
M Komatsu, T Schermerhorn, S G Straub and G W Sharp

Molecular Pharmacology October 1996, 50 (4) 1047-1054;

Main menu

User menu

Search

Table of Contents

In this issue

Navigate

More Information

ASPET's Other Journals